South Africa’s medicine regulator, Sahpra, has registered CAB-LA, a new anti-HIV jab. But for how much will drugmaker ViiV Healthcare sell it to the government? The Bhekisisa Centre for Health Journalism asked them in their TV programme Health Beat.
Bhekisisa editor-in-chief Mia Malan spoke to Dr Kimberly Smith, head of research and development at ViiV Healthcare, about the drug's pricing, clinical trials and availability.
This story was produced by the Bhekisisa Centre for Health Journalism. Sign up for the newsletter.
WATCH | Goal is to get price as low as possible, says HIV jab producer as Sahpra registers drug
South Africa’s medicine regulator, Sahpra, has registered CAB-LA, a new anti-HIV jab. But for how much will drugmaker ViiV Healthcare sell it to the government? The Bhekisisa Centre for Health Journalism asked them in their TV programme Health Beat.
Bhekisisa editor-in-chief Mia Malan spoke to Dr Kimberly Smith, head of research and development at ViiV Healthcare, about the drug's pricing, clinical trials and availability.
This story was produced by the Bhekisisa Centre for Health Journalism. Sign up for the newsletter.
MORE:
Covid-19 hit HIV detection in Europe, threatens eradication progress
Pay attention to young women and LGBTQI community to eradicate HIV, warn experts
LISTEN | SA to use injectable PrEP for HIV prevention instead of daily pill
World’s most expensive drug approved to treat haemophilia at R60m a dose
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
News and promos in your inbox
subscribeMost read
Latest Videos